<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="MEDLINE" Owner="NLM">        <PMID Version="1">30257941</PMID>        <DateCompleted>            <Year>2018</Year>            <Month>11</Month>            <Day>06</Day>        </DateCompleted>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>06</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1091-6490</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>115</Volume>                    <Issue>41</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>10</Month>                        <Day>09</Day>                    </PubDate>                </JournalIssue>                <Title>Proceedings of the National Academy of Sciences of the United States of America</Title>                <ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>            </Journal>            <ArticleTitle>ERβ-mediated induction of cystatins results in suppression of TGFβ signaling and inhibition of triple-negative breast cancer metastasis.</ArticleTitle>            <Pagination>                <MedlinePgn>E9580-E9589</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.1807751115</ELocationID>            <Abstract>                <AbstractText>Triple-negative breast cancer (TNBC) accounts for a disproportionately high number of deaths due to a lack of targeted therapies and an increased likelihood of distant recurrence. Estrogen receptor beta (ERβ), a well-characterized tumor suppressor, is expressed in 30% of TNBCs, and its expression is associated with improved patient outcomes. We demonstrate that therapeutic activation of ERβ elicits potent anticancer effects in TNBC through the induction of a family of secreted proteins known as the cystatins, which function to inhibit canonical TGFβ signaling and suppress metastatic phenotypes both in vitro and in vivo. These data reveal the involvement of cystatins in suppressing breast cancer progression and highlight the value of ERβ-targeted therapies for the treatment of TNBC patients.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Reese</LastName>                    <ForeName>Jordan M</ForeName>                    <Initials>JM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bruinsma</LastName>                    <ForeName>Elizabeth S</ForeName>                    <Initials>ES</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nelson</LastName>                    <ForeName>Adam W</ForeName>                    <Initials>AW</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge, CB2 1TN Cambridge, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Chernukhin</LastName>                    <ForeName>Igor</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge, CB2 1TN Cambridge, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Carroll</LastName>                    <ForeName>Jason S</ForeName>                    <Initials>JS</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Research UK Cambridge Institute, University of Cambridge, CB2 1TN Cambridge, United Kingdom.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Li</LastName>                    <ForeName>Ying</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Subramaniam</LastName>                    <ForeName>Malayannan</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Suman</LastName>                    <ForeName>Vera J</ForeName>                    <Initials>VJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN 55905.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Negron</LastName>                    <ForeName>Vivian</ForeName>                    <Initials>V</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Mayo Clinic, Rochester, MN 55905.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Monroe</LastName>                    <ForeName>David G</ForeName>                    <Initials>DG</Initials>                    <AffiliationInfo>                        <Affiliation>Robert and Arlene Kogod Center on Aging and Endocrine Research Unit, Mayo Clinic, Rochester, MN 55905.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ingle</LastName>                    <ForeName>James N</ForeName>                    <Initials>JN</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Mayo Clinic, Rochester, MN 55905.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Goetz</LastName>                    <ForeName>Matthew P</ForeName>                    <Initials>MP</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, Mayo Clinic, Rochester, MN 55905.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hawse</LastName>                    <ForeName>John R</ForeName>                    <Initials>JR</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN 55905; hawse.john@mayo.edu.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>P50 CA116201</GrantID>                    <Acronym>CA</Acronym>                    <Agency>NCI NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>R01 AR068275</GrantID>                    <Acronym>AR</Acronym>                    <Agency>NIAMS NIH HHS</Agency>                    <Country>United States</Country>                </Grant>                <Grant>                    <GrantID>MR/L00156X/1</GrantID>                    <Agency>Medical Research Council</Agency>                    <Country>United Kingdom</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>09</Month>                <Day>26</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>United States</Country>            <MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>            <NlmUniqueID>7505876</NlmUniqueID>            <ISSNLinking>0027-8424</ISSNLinking>        </MedlineJournalInfo>        <ChemicalList>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D015891">Cystatins</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D047629">Estrogen Receptor beta</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>            </Chemical>            <Chemical>                <RegistryNumber>0</RegistryNumber>                <NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>            </Chemical>        </ChemicalList>        <CitationSubset>IM</CitationSubset>        <CommentsCorrectionsList>            <CommentsCorrections RefType="Cites">                <RefSource>Oncogene. 2003 Oct 23;22(48):7600-6</RefSource>                <PMID Version="1">14576822</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Biochem. 2007 Aug 1;101(5):1125-47</RefSource>                <PMID Version="1">17520659</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Front Biosci (Landmark Ed). 2009 Jan 01;14:463-74</RefSource>                <PMID Version="1">19273078</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Rev Cancer. 2006 Oct;6(10):764-75</RefSource>                <PMID Version="1">16990854</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 2001 Mar 15;61(6):2537-41</RefSource>                <PMID Version="1">11289127</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>CA Cancer J Clin. 2017 Jan;67(1):7-30</RefSource>                <PMID Version="1">28055103</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2009 Nov 23;4(11):e7953</RefSource>                <PMID Version="1">19956729</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2014 Aug;146(3):657-67</RefSource>                <PMID Version="1">25007965</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Invest. 2009 Jun;119(6):1571-82</RefSource>                <PMID Version="1">19451693</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 1998 Mar 2;75(5):721-30</RefSource>                <PMID Version="1">9495240</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Physiol Rev. 2007 Jul;87(3):905-31</RefSource>                <PMID Version="1">17615392</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>BMC Cancer. 2014 Oct 07;14:749</RefSource>                <PMID Version="1">25288324</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23</RefSource>                <PMID Version="1">12829800</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Cell Biol. 2009 Nov;11(11):1287-96</RefSource>                <PMID Version="1">19838175</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Ann N Y Acad Sci. 2006 Nov;1089:119-26</RefSource>                <PMID Version="1">17261761</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2007 Jan 1;109(1):25-32</RefSource>                <PMID Version="1">17146782</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Cell Biochem. 2012 Feb;113(2):711-23</RefSource>                <PMID Version="1">22095450</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Endocrinol. 2013 Oct;27(10):1762-75</RefSource>                <PMID Version="1">23979844</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>PLoS One. 2016 Jun 16;11(6):e0157368</RefSource>                <PMID Version="1">27310713</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Endocrinology. 2001 Sep;142(9):4120-30</RefSource>                <PMID Version="1">11517191</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Clin Cancer Res. 2009 Apr 1;15(7):2302-10</RefSource>                <PMID Version="1">19318481</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 1999 Feb 1;59(3):529-32</RefSource>                <PMID Version="1">9973194</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Genomics. 1994 Nov 1;24(1):172-5</RefSource>                <PMID Version="1">7896273</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Diagn Pathol. 2014 Jan 23;9:20</RefSource>                <PMID Version="1">24457087</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pathol. 2003 Oct;201(2):213-20</RefSource>                <PMID Version="1">14517838</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>ISRN Mol Biol. 2012 Dec 24;2012:381428</RefSource>                <PMID Version="1">27340590</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2012 Nov 16;14(6):R148</RefSource>                <PMID Version="1">23158001</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Pathol. 2002 Dec;198(4):450-7</RefSource>                <PMID Version="1">12434414</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Cell Biol. 2009 Nov;11(11):1281-4</RefSource>                <PMID Version="1">19838176</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Natl Cancer Inst. 2017 Jul 1;109(7):</RefSource>                <PMID Version="1">28376176</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res. 2014 Feb 19;16(1):R21</RefSource>                <PMID Version="1">24552459</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer. 2011 Jun 15;117(12):2747-53</RefSource>                <PMID Version="1">21656753</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2016 Aug 2;7(31):49322-49333</RefSource>                <PMID Version="1">27384994</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Int J Cancer. 2000 Dec 1;88(5):733-6</RefSource>                <PMID Version="1">11072241</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Oncol. 2012 May 20;30(15):1796-804</RefSource>                <PMID Version="1">22508812</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Expert Opin Ther Targets. 2015 Jan;19(1):55-75</RefSource>                <PMID Version="1">25307277</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Oncotarget. 2017 Oct 11;8(57):96506-96521</RefSource>                <PMID Version="1">29228549</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2006 Nov;100(1):23-31</RefSource>                <PMID Version="1">16705367</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cancer Res. 2004 Mar;2(3):183-95</RefSource>                <PMID Version="1">15037657</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>EMBO J. 2009 May 20;28(10):1418-28</RefSource>                <PMID Version="1">19339991</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Cancer Res. 1998 Aug 1;58(15):3197-201</RefSource>                <PMID Version="1">9699641</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Nat Genet. 2011 Jan;43(1):27-33</RefSource>                <PMID Version="1">21151129</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Mol Cell Endocrinol. 2017 Jan 15;440:138-150</RefSource>                <PMID Version="1">27889472</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>JAMA. 2006 Jun 7;295(21):2492-502</RefSource>                <PMID Version="1">16757721</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>Breast Cancer Res Treat. 2015 Jul;152(2):255-69</RefSource>                <PMID Version="1">26070269</PMID>            </CommentsCorrections>            <CommentsCorrections RefType="Cites">                <RefSource>J Clin Invest. 2013 Mar;123(3):1348-58</RefSource>                <PMID Version="1">23391723</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <MeshHeadingList>            <MeshHeading>                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015891" MajorTopicYN="N">Cystatins</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D047629" MajorTopicYN="N">Estrogen Receptor beta</DescriptorName>                <QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D015398" MajorTopicYN="Y">Signal Transduction</DescriptorName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D064726" MajorTopicYN="N">Triple Negative Breast Neoplasms</DescriptorName>                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>                <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>            </MeshHeading>            <MeshHeading>                <DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName>                <QualifierName UI="Q000819" MajorTopicYN="N">agonists</QualifierName>                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>            </MeshHeading>        </MeshHeadingList>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="Y">TGFβ</Keyword>            <Keyword MajorTopicYN="Y">breast cancer</Keyword>            <Keyword MajorTopicYN="Y">cystatin</Keyword>            <Keyword MajorTopicYN="Y">estrogen receptor beta</Keyword>            <Keyword MajorTopicYN="Y">metastasis</Keyword>        </KeywordList>        <CoiStatement>The authors declare no conflict of interest.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="pmc-release">                <Year>2019</Year>                <Month>04</Month>                <Day>09</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>9</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>7</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>9</Month>                <Day>28</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>ppublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30257941</ArticleId>            <ArticleId IdType="pii">1807751115</ArticleId>            <ArticleId IdType="doi">10.1073/pnas.1807751115</ArticleId>            <ArticleId IdType="pmc">PMC6187171</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>